Literature DB >> 17669931

Should patients undergoing coronary artery bypass grafting with mild to moderate ischaemic mitral regurgitation also undergo mitral valve repair or replacement?

Aseem Ranjan Srivastava1, Amit Banerjee, Samuel Jacob, Joel Dunning.   

Abstract

A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was whether mitral valve repair at the time of coronary artery bypass grafting (CABG) in patients with coronary artery disease and mild to moderate mitral insufficiency improves short and long-term outcome. Altogether 465 papers were found using the reported search, of which 16 presented the best evidence to answer the clinical question. The author, journal, date and country of publication, patient group studied, study type, relevant outcomes, results, and study weaknesses of these papers are tabulated. We conclude that there is good evidence to suggest that moderate mitral regurgitation in patients undergoing isolated CABG adversely affects survival and mitral regurgitation does not reliably improve after CABG alone. Unfortunately, the evidence to support mitral valve repair at the time of CABG to improve long-term survival is still weak. On balance, patients with moderate ischaemic mitral regurgitation having CABG should have mitral repair at the same time, although the evidence to support this is weaker than one might like.

Entities:  

Mesh:

Year:  2007        PMID: 17669931     DOI: 10.1510/icvts.2007.157891

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  2 in total

1.  The Cardiothoracic Surgery Network: randomized clinical trials in the operating room.

Authors:  Timothy J Gardner; Patrick T O'Gara
Journal:  J Thorac Cardiovasc Surg       Date:  2010-04       Impact factor: 5.209

2.  Mitral valve repair for ischemic moderate mitral regurgitation in patients undergoing coronary artery bypass grafting.

Authors:  Faruk Toktas; Senol Yavuz; Kadir K Ozsin; Umut S Sanri
Journal:  Saudi Med J       Date:  2016-08       Impact factor: 1.484

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.